Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for children with low grade astrocytomas that have not responded
to standard therapy provide limited benefit to the patient. The anti-cancer properties of
Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with
low grade astrocytomas that have not responded to standard therapy
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on children (> 6 months of age) with low grade astrocytomas that
has not responded to standard therapy.